STOCK TITAN
  1. Home
  2. Sec-filings
  3. LKFT
  4. [6-K] Lakefront Biotherapeutics NV Current Report (Foreign Issuer)

Lakefront Biotherapeutics (NASDAQ: LKFT) details €2.73M share repurchase activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Lakefront Biotherapeutics reports progress under its previously announced share repurchase program, buying back 104,022 ordinary shares between 29 June and 3 July 2026. The company paid an average price of €26.24 per share, for a total of €2,730,010.70 across multiple European trading venues.

As of market close on 3 July 2026, Lakefront holds 303,756 of its own ordinary shares. Management reiterates that future repurchases involve uncertainties and are subject to risks outlined in its SEC filings, and it includes standard forward-looking statement cautions.

Positive

  • None.

Negative

  • None.
Shares repurchased 104,022 shares Repurchase period 29 June–3 July 2026
Average repurchase price €26.24 per share Weighted average across all trades
Total repurchase amount €2,730,010.70 Consideration for 104,022 shares
Treasury shares held 303,756 shares As of market close on 3 July 2026
Lowest price paid €25.60 per share During 29 June–3 July 2026 repurchases
Highest price paid €26.88 per share During 29 June–3 July 2026 repurchases
repurchase program financial
"Within the framework of the repurchase program announced on June 9, 2026"
A repurchase program is when a company buys back its own shares from the open market. This reduces the total number of shares available, which can increase the value of each remaining share and signal confidence in the company's future. For investors, it often suggests that the company believes its stock is undervalued and can be a sign of financial strength.
regulated information regulatory
"Mechelen, Belgium; 07 July 2026, 22.01 CET; regulated information"
BCMAxCD3 T-cell engager technical
"anchored by gamgertamig, a potential first-in-class BCMAxCD3 T-cell engager"
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Private Securities Litigation Reform Act of 1995 regulatory
"forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What did Lakefront Biotherapeutics (LKFT) announce in this Form 6-K?
Lakefront Biotherapeutics reported recent activity under its share repurchase program. It repurchased 104,022 ordinary shares between 29 June and 3 July 2026 and disclosed the prices paid, total consideration, and its total treasury share position after these transactions.

How many Lakefront Biotherapeutics (LKFT) shares were repurchased and at what cost?
Lakefront repurchased 104,022 ordinary shares for a total of €2,730,010.70. The average price paid was €26.24 per share, with individual trades executed across several European trading venues within a narrow price range around this average.

Over what period did Lakefront Biotherapeutics (LKFT) conduct these share buybacks?
The company conducted the reported share repurchases from 29 June 2026 through 3 July 2026. During this period, it executed multiple trades each day across different markets, all within its ongoing repurchase program announced earlier on 9 June 2026.

How many treasury shares does Lakefront Biotherapeutics (LKFT) now hold?
As of market close on 3 July 2026, Lakefront holds 303,756 of its own ordinary shares. This figure reflects the cumulative effect of the repurchase activity reported in this update, within the broader share buyback program previously announced by the company.

What price range did Lakefront Biotherapeutics (LKFT) pay for the repurchased shares?
The reported trades show a lowest price paid of €25.60 per share and a highest price paid of €26.88 per share. Within this range, the company’s weighted average purchase price across all 104,022 repurchased shares was €26.24 per share.

Does Lakefront Biotherapeutics (LKFT) include any forward-looking statements in this update?
Yes. The company includes forward-looking statements, particularly about its plans to repurchase ordinary shares. It cautions that these statements involve risks and uncertainties and refers investors to its Form 20-F and other SEC filings for detailed risk factors.
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission File Number: 001-37384

Lakefront Biotherapeutics
(Translation of registrant's name into English)

Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).

On July 7, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit 99.1. Press release dated July 7, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Lakefront Biotherapeutics    
  (Registrant)
   
  
Date: July 7, 2026     /s/ Ying Deng    
  Ying Deng
  Authorized Officer
  

EXHIBIT 99.1

Acquisition of Own Shares

Mechelen, Belgium; 07 July 2026, 22.01 CET; regulated information

Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 104,022 Lakefront shares between 29 June 2026 and 03 July 2026, as follows:

Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€)
29/06/2026 XAMS 14,414 25.75 371,205.18 25.60 26.00
29/06/2026 CEUX 3,399 25.74 87,478.36 25.66 26.00
29/06/2026 TQEX 696 25.71 17,897.29 25.66 26.00
29/06/2026 AQEU 916 25.71 23,551.83 25.66 25.80
30/06/2026 XAMS 19,724 26.37 520,179.08 25.98 26.74
30/06/2026 CEUX 2,068 26.45 54,694.67 26.22 26.72
30/06/2026 TQEX 508 26.53 13,478.15 26.14 26.78
30/06/2026 AQEU 445 26.09 11,610.94 26.08 26.12
01/07/2026 XAMS 20,787 26.30 546,681.47 26.06 26.48
01/07/2026 CEUX 2,613 26.20 68,467.39 26.12 26.44
01/07/2026 TQEX 71 26.40 1,874.32 26.32 26.40
01/07/2026 AQEU 198 26.17 5,181.78 26.16 26.30
02/07/2026 XAMS 13,778 26.14 360,180.34 25.88 26.54
02/07/2026 CEUX 3,021 26.06 78,727.86 25.96 26.12
02/07/2026 TQEX 115 26.23 3,015.94 25.96 26.46
02/07/2026 AQEU 721 26.12 18,835.04 25.96 26.14
03/07/2026 XAMS 15,162 26.62 403,642.76 26.46 26.86
03/07/2026 CEUX 4,786 26.59 127,266.92 26.50 26.86
03/07/2026 TQEX 526 26.75 14,071.18 26.50 26.88
03/07/2026 AQEU 74 26.62 1,970.16 26.52 26.64
Total   104,022 26.24 2,730,010.70 25.60 26.88

As of market close on 03 July 2026, Lakefront holds 303,756 of its own ordinary shares.

About Lakefront Biotherapeutics
Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.

For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com

Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases